Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Is at least 6 weeks postpartum at the time of administration of study intervention, following the delivery of a healthy singleton neonate
Is willing and able to express breast milk at least twice daily for at least 120 hours after enrollment
Is willing to discontinue breastfeeding from the time of administration of study intervention until at least 6 weeks following the administration of study intervention. This includes the avoidance of both directly breastfeeding and the administration of breast milk pumped during the above-specified time frame to the infant. Is willing to confirm with the site that the infant is able to bottle feed (breast milk) prior to Day 1 and that alternative nutrition (i.e., previously stored breast milk or infant formula) is available for feeding the infant through the 6-week post dose period
You may not be if
Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, psychiatric, or major neurological (including stroke and chronic seizures) abnormalities or diseases
Had mastitis within 30 days prior to administration of study drug
Has a positive pregnancy test at the time of screening or prior to treatment allocation
Clareo Health | A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)
